Dr. Jeff Myers

Chief Medical Officer

Dr. Jeff Myers, MD, PhD is an experienced biotech executive with experience in all phases of drug development and business development. Dr. Myers previously practiced as a congenital cardiac surgeon prior to entering industry. He served as the Chief of Pediatric Cardiac Surgery at The Massachusetts General Hospital and Associate Professor for Surgery at Harvard Medical School prior to beginning his career in industry. His PhD work was in cardiovascular physiology and he led an independent laboratory studying pulmonary hypertension resulting in multiple peer-reviewed articles and textbook chapters.

Dr. Myers’ industry experience includes a variety of therapeutic areas including cardiovascular, pulmonary, oncology, and inflammatory diseases. While at Gilead he was the Global Medical Affairs Lead for the CV franchise including pulmonary hypertension, chronic angina, and cystic fibrosis; a franchise with over $1.1 billion in annual sales. Subsequently at SteadyMed he was instrumental in the clinical development of Trevyent as the Regulatory lead guiding the development program through the 505(b)(2) pathway until the company was acquired by United Therapeutics. Most recently, Dr. Myers served as the SVP of Global Medical Affairs and Interim CMO at Portola Pharmaceuticals through the eventual acquisition by Alexion. At Portola he was responsible for the development of cerdulatinib, an oral SYK/JAK inhibitor and it the marketed drug Andexxa, a novel agent for reversal of anti-Xa inhibitors.

Outside of clinical practice and industry experience, Dr. Myers has a distinguished academic and philanthropic history with multiple Professional Society memberships including being one of the youngest members ever initiated into the Congenital Heart Surgeons Society. In addition, as a member of the Mayo Clinic’s organization, Children’s Heartlink, he has performed surgery on critically ill children and developed programs around the world including China and Africa. Along with his wife Dahri he began the Myers’ Family Endowment at Tulane dedicated to STEM education of K-12 age children of New Orleans and linking them with Tulane faculty to encourage careers in science and technology.